Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

Risk factors for stroke climbing in Native Americans

A study of Native Americans who experienced ischemic stroke showed they carried a high burden of risk factors, nearly all of which grew in prevalence from 2000 to 2016.

Thumbnail

Climate change could push CHD rates 62% higher by 2035

A projected increase in extreme weather driven by climate change could have a lasting effect on expectant mothers and their children, according to a study that recently linked maternal heat exposure to an elevated risk of congenital heart defects (CHDs) in the U.S.

Thumbnail

DOACs overtaking warfarin as go-to anticoagulant for Medicaid patients

Direct oral anticoagulants (DOACs) are on their way to surpassing warfarin as the anticoagulant of choice among Medicaid beneficiaries, despite their higher cost, according to new research published in the Journal of the American College of Cardiology.

Thumbnail

Tachycardia in cancer patients linked to poor survival

Cancer patients who experienced tachycardia within one year of being diagnosed carried higher mortality rates up to a decade later—even after adjusting for clinical characteristics and medication use—according to research presented Jan. 25 at the Advancing the Cardiovascular Care of the Oncology Patient conference.

Thumbnail

Younger breast cancer patients see elevated long-term risk for AFib

Breast cancer patients under 60 years old are nearly twice as likely as their healthy counterparts to develop both short- and long-term atrial fibrillation (AF), researchers reported Jan. 29 in Heart Rhythm.

Thumbnail

Knowledge sharing, device improvements may shrink TAVR learning curve

A new analysis published in the Journal of the American College of Cardiology suggests the learning curve for achieving the best transcatheter aortic valve replacement (TAVR) outcomes may have dissipated with a current-generation, balloon-expandable device.

Thumbnail

Dapagliflozin lowers CV risk in type 2 diabetics

The blood sugar drug dapagliflozin was declared noninferior to placebo in the recent DECLARE-TIMI 58 trial, and while the medication failed to lower rates of major adverse cardiovascular events (MACE) in subjects, it did reduce rates of CV-related death and hospitalizations for heart failure.

Thumbnail

Setting an example: Transplant surgeon accepts heart with hepatitis C

Knowing he needed a new heart, Robert Montgomery, MD, saw an opportunity to practice what he preaches. So, the 58-year-old director of NYU Langone Health’s Transplant Institute accepted an organ from a heroin user who died of a drug overdose and had hepatitis C.